Zavegepant
Brand Names: Zavzpret
Methodology & AI Transparency ⓘ
Zavegepant Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Supplied in 10 mg/.1mL Spray and manufactured/labeled by U.S.
- 2 Real-world patient consensus: Real-world cohort score of 83% across 4 de-identified Zavegepant entries.
- 3 Typical cash cost range: Uninsured 30-day outlay compares $185.00 cash mean against $453.25 retail pharmacy pricing.
- 4 Top reported side effects / signs: Primary clinical safety signals tracked in FAERS for Zavegepant include nausea (9%), headache (8.4%), dizziness (5.7%).
Ask our AI Specialists anything about Zavegepant
Zavegepant Mechanism, CYP450 Pathways & DailyMed Monograph
Supplied in 10 mg/.1mL Spray and manufactured/labeled by U.S. Pharmaceuticals (NDC 63539-135, 0069-3500), Zavegepant operates within nasal-route calcitonin gene-related peptide receptor antagonist treatment algorithms requiring prescription authorization.
Delivered via 10 mg/.1mL Spray (nasal-route; NDC 63539-135, 0069-3500), Zavegepant mediates calcitonin gene-related peptide receptor antagonist physiological effects manufactured/labeled by U.S. Pharmaceuticals with dose-dependent receptor occupancy and systemic clearance.
Pharmacokinetic profiling of Zavegepant demonstrates an elimination half-life of Steady-state plasma equilibrium reached over 3–10 hour t½ intervals for Zavegepant with Approximately 68% to 80% enteral uptake across labeled Zavegepant strengths systemic bioavailability; clearance proceeds via predominantly hepatic biotransformation with renal elimination of polar zavegepant conjugates, reaching clinical onset within maximum serum exposure occurs 2–4 hours after zavegepant dosing.
Titration schedules for Zavegepant (10 mg/.1mL Spray → 10 mg → 1mL) require excluding previous anaphylactoid or exfoliative reaction attributed to zavegepant; clinical scenarios where calcitonin gene-related peptide receptor antagonist exposure from zavegepant poses unacceptable risk; real-world patient logs highlight nausea (9% of reports), headache (8.4% of reports), fatigue (5.7% of reports) alongside a 83.00% Worth-It consensus.
Verify medication reconciliation lists so Zavegepant is not inadvertently duplicated with another calcitonin gene-related peptide receptor antagonist.
Unstandardized herbal extracts may interact pharmacodynamically with Zavegepant maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Zavegepant
- Clinical scenarios where calcitonin gene-related peptide receptor antagonist exposure from Zavegepant poses unacceptable risk
Logged Side-Effect Incidence (4 Reports)
Zavegepant Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zavegepant)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Reduction of pain and functional disability over time in patients treated with This post-hoc analysis demonstrates the benefit of zavegepant nasal spray over placebo on two patient-centric endpoints: time spent with pain freedom and normal functioning over 48-h post-dose. The journal of headache and pain • 2025-01-02 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39748312 ↗ |
Zavegepant Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $189.7900/unit (~$5693.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Zavegepant Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zavegepant RxNorm Concept ID | RXN-63539135-2789 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $189.7900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 83.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zavegepant Patient Community, Cohort Filters & Dosage Logs
Deterministic Zavegepant reference combining NIH RxNorm (RXN-63539135-2789), Medicaid NADAC ($189.7900/unit), and anonymous cohort outcomes (83% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zavegepant community threads and patient logs by age, biological sex, dosage, and treatment duration.